MoU signed for commercial production of indigenously developed vaccine ‘Lumpi-ProVac’

Tags: Science and Technology National News

An MoU for the production of Goat Pox Vaccine and “Lumpi-Provac” vaccine was signed in Nagpur on December 29, 2022 in the presence of Union Minister of Fisheries, Animal Husbandry, Parshottam Rupala and Chief Minister of Maharashtra Eknath Shinde.

Important facts

• Rupala praised the commendable effort put forth by ICAR in developing indigenous vaccine Lumpi-ProVac for LSD.

• Lumpi-ProVaccine is used for the prophylactic immunization of animals against Lumpy Skin Disease.

• The vaccine technology will meet the standard of the market and significantly provide a defence mechanism to control the devastating lumpy skin disease.

• Goat pox vaccine is currently used to control lumpy Skin Disease in livestock and has been shown to be effective against lumpy.

• Union Minister Rupala further highlighted the relevance of the technology and requested the IVBP, Pune to start manufacturing the vaccine at a large scale without any delay. 

• National Centre for Veterinary Type Culture, ICAR-National Research Centre on Equines (ICAR-NRCE), Hisar (Haryana), in collaboration with ICAR-Indian Veterinary Research Institute (IVRI), Izatnagar (UP) developed a homologous live-attenuated LSD vaccine, named Lumpi-ProVacInd.

• Agrinnovate India Limited  (AgIn), the commercial arm of DARE, Ministry of Agriculture and Farmers’ Welfare, granted  “Non-Exclusive Rights” for Commercial production of “Lumpi-ProVac”, to Institute of Veterinary Biological Products (IVBP) , Pune.

Lumpy Skin Disease

• It is caused by infection of cattle or  buffalo with the poxvirus Lumpy skin disease virus (LSDV).

• The virus is one of three closely related species of the genus Capripoxavirus.

• The other two species are Sheeppox virus and Goatpox virus.

• Due to its infectious nature and its impact on the economy, the World Organization for Animal Health (WOIE) has declared it a notable disease.